This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).

The proposed trial will be embedded within clinical care. This is a 2-year interventional trial that will enroll patients with active psoriatic arthritis despite stable therapy among three centers (the University of Pennsylvania, University of Utah, and University of Oxford). The intervention employs PsOWellTM, a program that trains clinicians to utilize motivational interviewing to help patients set goals and make lifestyle/behavior changes for holistic management of psoriasis.

Inclusion Criteria:

• Population: Patients with Psoriatic Arthritis

  • Age 18-89.
  • Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score >4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10).
  • Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit).
  • Meet CASPAR criteria.
  • Provision of signed and dated informed consent form.
  • Willingness to comply with all study procedures and availability for duration of the study.
  • Has access to a mobile phone or other mobile device.

Exclusion Criteria:

• Inability to provide informed consent.
• Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks.
• PsAID score ≤4

Fully de-identified datasets will be shared with requesting parties after manuscript publication and following submission of a protocol by the requesting party and approval by the study investigators.

As a pilot study to understand implementation barriers, assess feasibility, and effectiveness, this study is not blinded or randomized.